NDLI: The effect of raloxifene treatment in postmenopausal women with CKD.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Ishani, Areef Blackwell, Terri Jamal, Sophie A. Cummings, Steven R. Ensrud, Kristine E.
Description	Country affiliation: United States Author Affiliation: Ishani A ( Center for Chronic Disease Outcomes Research, Veterans Affairs Medical Center, and Department of Medicine and Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN 55417, USA. isha0012@umn.edu)
Abstract	It is unknown whether treatment for osteoporosis with raloxifene is safe or effective in those with chronic kidney disease (CKD). With data from a multicenter, randomized, placebo-controlled trial of 7705 postmenopausal women with osteoporosis, the effect of raloxifene on rate of change of bone mineral density (BMD), incidence of fractures, and adverse events by stage of CKD was examined over 3 yr. Baseline serum creatinine values were available for 7316 women, and these values were used to assign a category of creatinine clearance (CrCl) using the Cockcroft-Gault formula (CrCl < 45, 45 to 59, and > or = 60 ml/min). BMD was measured at baseline and annually by dual x-ray absorptiometry. Within the placebo group, lower baseline CrCl was associated with a trend for higher annual losses of BMD at the femoral neck; however, within the raloxifene group, lower baseline CrCl was associated with greater increases in femoral neck BMD. This interaction between category of CrCl and treatment assignment was significant for rate of change of BMD at the hip. Irrespective of kidney function, raloxifene treatment was associated with a greater increase in spine BMD, a reduction in vertebral fractures, and no effect on nonvertebral fractures compared with placebo. Within each category of kidney function, adverse events were similar between the raloxifene and placebo groups. In conclusion, raloxifene increases BMD at both the hip and the spine and reduces the risk for vertebral fractures among individuals with CKD. The effect ofraloxifene on hip BMD is greater among those with mild to moderate CKD.
File Format	HTM / HTML
ISSN	10466673
e-ISSN	15333450
DOI	10.1681/ASN.2007050555
Journal	Journal of the American Society of Nephrology
Issue Number	7
Volume Number	19
Language	English
Publisher	American Society of Nephrology
Publisher Date	2008-07-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Nephrology Bone Density Conservation Agents Therapeutic Use Kidney Failure, Chronic Complications Osteoporosis, Postmenopausal Drug Therapy Raloxifene Bone Density Drug Effects Adverse Effects Spinal Fractures Etiology Prevention & Control Multicenter Study Randomized Controlled Trial
Content Type	Text
Resource Type	Article
Subject	Nephrology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.

A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.

Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial

Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.

Benefits and risks of raloxifene by vertebral fracture status.

Medikamentöse Therapie von Knochenstoffwechselstörungen bei CKD-MBD ('chronic kidney disease - mineral bone disorder') unter besonderer Berücksichtigung antiresorptiver Wirkstoffe.

Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial.

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis: A Randomized Controlled Trial

Long-term raloxifene for postmenopausal osteoporosis.

The effect of raloxifene treatment in postmenopausal women with CKD.

Similar Documents

Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.

A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.

Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial

Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.

Benefits and risks of raloxifene by vertebral fracture status.

Medikamentöse Therapie von Knochenstoffwechselstörungen bei CKD-MBD ('chronic kidney disease - mineral bone disorder') unter besonderer Berücksichtigung antiresorptiver Wirkstoffe.

Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial.

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis: A Randomized Controlled Trial

Long-term raloxifene for postmenopausal osteoporosis.

The effect of raloxifene treatment in postmenopausal women with CKD.